INTRODUCTION
============

Attention deficit hyperactivity disorder (ADHD) is a prevalent childhood-onset disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity and impulsivity. According to the symptomatic phenomenology, children with ADHD are diagnosed as predominantly inattentive type (ADHD-IA), predominantly hyperactive/impulsive type (ADHD-HI), or combined type (ADHD-C) (DSM-IV). Although ADHD is considered as a major public health problem with a worldwide pooled prevalence of 5.29%, the etiology of ADHD remains poorly understood.[@B1] ADHD is a highly heritable developmental disorder caused by the interaction of both environmental and genetic factors that result in the interruption of neural growth process.[@B2] Despite the important role of environmental factors in the etiology of ADHD, evidence from classical genetic studies has revealed a strong genetic component to ADHD development. The risk of ADHD among parents whose children have ADHD is 2 to 8 times higher than the general population incidence. A meta-analysis of 20 pooled twin studies indicated an estimated average heritability of 76%, suggesting that ADHD has a strong genetic component.[@B3] Methylphenidate is an effective treatment for ADHD symptoms, and recent studies evaluating the genetic risk factors associated with ADHD have focused on genes that regulate dopamine and noradrenaline neurotransmission.[@B4] However, the heterogeneous nature of ADHD symptoms led the authors to propose that ADHD subtypes may be distinguished from each other by treatment response and genetic etiology.[@B5] Two polymorphisms of interest are rs4680, found in the *COMT* gene, and rs1800544, which is found in the *ADRA2A* gene.

The COMT enzyme catalyzes the transfer of methyl groups in the catabolism of catecholamines. A functional SNP at codon 158 of *COMT* (rs4680) results in a single amino acid change (methionine for valine) that significantly alters enzyme activity.[@B6] Val/Val genotype at this SNP was shown to impair pre-frontal cognitive functions.[@B7] However, the results of many *COMT* polymorphism studies are controversial. While a higher incidence of Val/Val was found in children with ADHD who exhibited better treatment responses,[@B8] in other population studies[@B9][@B10][@B11][@B12] as well as in a recent meta-analysis,[@B13] no association was found between *COMT* genotype and ADHD diagnosis or symptom severity.

It has been suggested that methylphenidate improves attention by stimulating the alpha2-adrenergic receptors present in dopamine-containing neurons.[@B14][@B15][@B16] The 1252 G-to-C SNP, which results in an *Msp*I site (also known as C-1291G) (rs1800544) in the promoter region of *ADRA2A* and a A-to-G polymorphism in the 3\' untranslated region (3\'-UTR) known as the *Dra*I site (rs553668), are the two major polymorphisms that have been investigated in ADHD patients. To date, major pharmacogenetic studies have evaluated the role of the rs1800544 in the *ADRA2A* promoter region and some have associated the G allele with improved MPH response.[@B17][@B18] Furthermore, inattention symptoms are associated with rs1800544.[@B19][@B20]

Given the results of prior research into the genetics of ADHD, the role of *COMT* and *ADRA2A* polymorphisms remains uncertain. In this naturalistic study, we evaluated the relationship of the *ADRA2A* rs1800544 and *COMT* rs4680 SNPs with ADHD subtypes and specific clinical characteristics of ADHD, including highly homogenous patient populations such as treatment-resistant patients and patients with increased psychiatric symptom severity. We hypothesized that rs1800544 would be more common in ADHD-IA and rs4680 would be more prevalent in the ADHD-C subtype. We also evaluated the relationship between rs4680 and high symptom severity, reduced response to treatment, low SES, impaired familial functionality, low clinical functionality, and increased psychiatric comorbidity incidence.

METHODS
=======

Patients
--------

121 ADHD patients aged 6--18 years were recruited from the Hacettepe University Child and Adolescent Psychiatry Department. All study participants met the DSM-IV ADHD diagnostic criteria based on clinical assessment. The patients included in the study were stimulant naive and did not receive concurrent psychotropic medications. Diagnosis and ADHD subtype were confirmed using the K-SADS.[@B21] Children having comorbid disorders such as mental retardation, anxiety disorders, mood disorders, autism spectrum disorders, psychosis, substance use disorders as well as chronic and neurological diseases were excluded, while patients with comorbid oppositional defiant disorder, conduct disorder, and learning disorder were included. The Wechsler Intelligence Scales for Children (WISC-R or WISC-4) were applied to identify cases of mental retardation.[@B22][@B23] Patients with an IQ below 70 according to the WISC-R and below 70 on the perceptual reasoning or verbal comprehension portion of the WISC-4 were excluded from the study group. The diagnosis of Learning Disorder was made using the Learning Disorder Battery to supplement clinical assessment.[@B24] Patients were treated in our clinic with methylphenidate according to commonly accepted regimens.[@B25] The dose range of methylphenidate was 0.7--1.1 mg/kg per day and doses were augmented during follow-up until no further clinical improvement was detected or until there were limiting adverse effects. Our study was approved by the local Ethics Committee and conducted in accordance with the Declaration of Helsinki. All patients and parents provided written informed consent. The control group was composed of 102 banked DNA samples stored in the Hacettepe University, Medical Genetics Department from a population with a similar gender distribution.

Clinical assesment
------------------

The sociodemographic, developmental and clinical features were assessed for each patient during a parent interview carried out by a child and adolescent psychiatrist at baseline. SES was classified in 5 levels according to the Hollingshead-Redich Scale (level 1--2 representing low, 3 representing middle and 4--5 representing high SES). The ADHD symptoms were evaluated by the CPRS and CTRS.[@B26] The clinician-rated CGI-S was used to assess the severity of symptoms (scoring from 1 to 7 points, 7 for the most severe) and patients who scored 3 or greater were classified as the high symptom severity group. The GAS was used to asses functionality (scoring from 0 to 100, 100 representing the most functional) and patients who scored below 60 points were categorized as the low functionality group. TMT A and B[@B27] and Conners\' CPT[@B28] were used to assess neuropsychological deficits in the patient group. In all patients, peripheral venous blood was collected to determine genotype at the *ADRA2A* and *COMT* SNPs at the Hacettepe University, Medical Genetics Department. As ADHD is a highly heritable disorder, the parents\' ADHD symptoms were evaluated using the Wender Utah Rating Scale.[@B29] Familial functionality was assessed using the McMaster Familial Assessment Scale.[@B30]

Four-to-six weeks after initiation of methylphenidate treatment, the patients underwent the same naturalistic assessment procedure to evaluate the treatment response, which included the reapplication of the CPRS, CTRS, CGI-S, GAS, CPT and TMT A and B. 13 of 121 patients did not comply with the drug treatment and withdrew from the study prior to the treatment response assessment. Treatment responders were defined as follows: patients registering 2 points or greater improvement on the CGI-S[@B31] and a total GAS score of 60 points or greater, corresponding to a minimum of 50% improvement on any of the sub-scales of CPRS/CTRS,[@B32] or improvement in one of the neuropsychological tests[@B33] applied at follow-up.

Genotyping
----------

### Detection of rs1800544 in *ADRA2A* and rs4680 in *COMT*

Genomic DNA was isolated by salt precipitation from peripheral blood leukocytes of 121 participants with ADHD and 102 gender-matched controls. *ADRA2A-F* (5\'-TCACAC CGGAGGTTACTTCCCTCG-3\'), *ADRA2A-R* (5\'-TCCGA CGACAGCGCGAGTT-3\') and *COMT-F* (5\'-ACTGTGGC TACTCAGCTGTG-3\'), *COMT-R* (5\'-CCTTTTTCCAGG TCTGACAA-3\') primer pairs were used for PCR amplification of DNA segments flanking rs1800544 and rs4680, respectively. Restriction enzyme digestion was carried out using *Msp*I and *Hsp92*II (New England Biolabs, MA, USA) to genotype DNA samples for the rs1800544 variation in *ADRA2A* and rs4680 variation in *COMT*, respectively, using a protocol modified from previous studies.[@B34][@B35] Allele designations for *ADRA2A* and *COMT* are according to the NCBI reference sequences and the dbSNP database (NM_000681.3 and NM_001135162.1, respectively) (<http://www.ncbi.nlm.nih.gov>, [www.dbsnp.com](http://www.dbsnp.com)).

Statistical analysis
--------------------

All statistical analyses were performed using SPSS (version 21.0). The Shapiro-Wilk test was used to assess the adherence to the normal distribution assumption. Homogeneity of variance among the groups was tested using Levene\'s test. Differences in numeric variables were evaluated using a Student\'s t-test for independent samples. The Mann-Whitney U test was performed when the parametric test hypothesis was not supported, indicating the presence of a non-normal distribution. The Kruskal-Wallis test was used for the comparison of numeric variables among more than two groups. Differences in numeric variables before and after treatment were evaluated using the Wilcoxon test for dependent samples. Between group comparisons involving categorical data were carried out using either the χ^2^ test or Fisher\'s exact test. Differences in categoric variables before and after treatment were assessed using the McNemar test. Factors associated with treatment outoutcome were evaluated using multiple logistic regression analysis. Results were considered statistically significant when p\<0.05.

RESULTS
=======

Demographic data
----------------

The sociodemographic and clinical characteristics of our sample are summarized in [Table 1](#T1){ref-type="table"}.

Clinical data
-------------

In this naturalistic study, mean methylphenidate dosage was 0.7 mg/kg/day. 9.1% of the patients used short acting methylphenidate and 80.2% used long acting methylphenidate.

In the first assessment, all CPRS and CTRS sub-scale scores were increased among patients with the combined ADHD subtype compared to patients with the predominantly inattentive subtype. After treatment, there was a significant decrease in CGI-S and improvement in GAS scores (p\<0.05). In addition, the CPRS and CTRS sub-scale scores were significantly decreased at the second evaluation (p\<0.05), with the exception of the psychosomatic sub-scale score. However, there was no significant relationship between improvement on any of the CPRS/CTRS sub-scales and DSM-IV subtype. In the neuropsychological tests, TMT A and B completion time as well as the number of errors and corrections that occurred during these tests were significantly decreased after treatment (p\<0.05). The CPT latency period was decreased and omission/commission error rates decreased after treatment (p\<0.05).

Genotype frequencies did not differ between the study and the control groups ([Table 2](#T2){ref-type="table"}). There was no evidence for any relationship between rs4680 and ADHD subtype, symptom severity, global functionality, familial functionality, SES, or treatment response. The distribution of genotypes in patient group according to ADHD subtypes and treatment response is shown in [Table 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively. While *COMT* genotypes were not associated with any of the CPRS/CTRS sub-scales, GC and GG alleles for the rs1800544 polymorphism were associated with the learning problems CPRS sub-scale and the CTRS attention deficiency sub-scale (p\<0.05). In addition, there was no difference in the distribution of COMT genotypes according to psychiatric co-morbidities.

Treatment response data
-----------------------

Among the 108 patients that had been assessed for treatment response, 66.6% responded to the treatment, while 33.3% did not. ADHD subtype was not associated with differences in treatment response. We used multiple logistic regression analysis to examine the relationship between various clinical parameters and treatment response. ADHD subtype, *COMT* genotypes, *ADRA2A* genotypes, low SES, presence of comorbid psychiatric disorder, presence of prenatal-natal-postnatal problems, presence of medical comorbidity, low parental education level, overcrowded house and age met the criteria for inclusion in the multivariate analysis (p\<0.25). The results indicated that *ADRA2A* GG genotype (OR=5.6), the presence of a psychiatric comorbidity (OR=5.6) and low SES (OR=2.3) were associated with reduced response to methylphenidate treatment. Logistic regression analysis is shown in [Table 5](#T5){ref-type="table"}.

DISCUSSION
==========

In this naturalistic study, we explored the relationship between two SNPs, *ADRA2A* rs1800544 and *COMT* rs4680, and ADHD phenotype, including ADHD subtype, treatment resistance, and psychiatric symptom severity.

There was no significant difference in the frequency of the two genotypes between the patient and the control groups. Although previous studies have shown that these polymorphisms were more common in the ADHD patient group compared to the general population,[@B8][@B36] other reports have indicated no difference in SNP distribution.[@B13][@B37] These results may be attributable to the multi-genic nature of ADHD. These polymorphisms may play a relatively small role as modifiers of ADHD etiology that are difficult to detect in small study groups. While the distribution of rs4680 genotypes in the present study was similar to previously reported distributions,[@B8] this was not the case for rs1800544.[@B20][@B36][@B38] This *ADRA2A* polymorphism occurred at a similar rate in both patient and control groups. This may be attributable to ethnic differences between the study groups.

In the present study, there was no association between high symptom severity, low clinical functionality and *COMT* polymorphism; as in some of the prior studies.[@B11][@B12][@B13] Only the rs4686 haplotype of *COMT* SNP was evaluated in this study and it was therefore not possible for us to estimate the effects of other haplotype on ADHD risk. Other evidence suggests that *COMT* haplotypes may lead to changes in enzyme activity.[@B39][@B40] Consequently, additional studies including other haplotypes of *COMT* must be carried out to evaluate the possible roles of *COMT* variations in ADHD etiology.

We did not observe significant differences in genotype distribution according to ADHD subtype. However, the methionine allele rs4680 was more common in the combined subtype patient group, although this observation was not statistically significant. Contradicting studies investigating relationships between SNPs and ADHD subtypes have been reported in literature. While, the presence of the the valine allele at rs4680 in *COMT* has been associated with aggression, and indirectly with combined subtype in some studies,[@B41][@B42] other reports indicate increased frequency of the methionine allele among patients with inattentive subtype ADHD[@B43] and executive function defects. Executive functions can be directly impaired by valine allele, which results in high enzyme activity and low dopaminergic prefrontal status.[@B13] Executive functions can also be augmented by the methionine allele, which causes low enzyme activity.[@B44] Executive functions are not only relevant to attention, organization, and planning, but also impulsivity. This may account for the higher frequency of the memethionine allele in the combined ADHD subtype group in the present study.

Although, we observed no relationship between rs1800544 frequency and predominantly inattentive subtype ADHD, there are examples of such cases in the literature.[@B17][@B38] However, the presence of the G allele at rs1800544 was associated with the learning problems CPRS sub-scale score and attention deficiency CTRS sub-scale score in the present study. Similar findings have been reported using alternate ADHD symptom scales.[@B20][@B38][@B45] On the contrary, Wang et al.[@B46] found no relation between rs1800544 and ADHD symptoms. In our study, we found no association between *COMT* genotype and CPRS or CTRS sub-scales, as has been reported by Tahir et al.[@B11] and challenged by other reports in the literature.[@B41][@B42] As a result, the association of rs1800544 with CPRS and CTRS sub-scale scores implies that phenotypic discrimination by *ADRA2A* polymorphisms may be important. However, current ADHD subtypes may be inadequate to provide enough homogeneity for reliable phenotyping of ADHD. Hence, future genetic studies for these polymorphisms together with phenotyping on the basis of symptoms may provide more specific evidence.

In the present study, we found no association between rs4680 (*COMT*) and the presence of other psychiatric co-morbidities, in contrast to the findings of other studies.[@B41][@B43] In addition, we found no correlation between low SES and rs4680 frequency. This may be due to a selection bias resulting from the conduct of the study at a tertiary medical center with few patients of low SES (9.1%). The largest proportion of participants were classified in the middle SES group (48.8%). rs4680 was not associated with low familial functionality in this study. This may occur as a result of consistently low familial functionality throughout the study group. To our knowledge, this is the first study to explore the relationship between these polymorphisms and familial functionality in Turkish ADHD patients.

*COMT* polymorphism was not associated with treatment response in the univariate analysis, similar to prior studies.[@B11][@B47][@B48] However, the valine allele for rs4680 (*COMT*) was more frequent among treatment responders relative to prior reports.[@B8][@B13] In accordance with the results of Solanto et al.[@B49] ADHD subtype was not associated with treatment response. However, this finding conflicts with reported differences in treatment response associated with ADHD subtype.[@B50][@B51] In multiple regression analysis, low SES and the presence of psychiatric co-morbidities were associated with poor treatment response. Other studies have reported similar conclusions.[@B50][@B52] This association may be attributable to poor adherence to treatment in low SES groups and the complexity of treatment procedures caused by psychiatric co-morbidities. Surprisingly, the GG genotype in rs1800544 was associated with poor treatment response in the present study. This is in opposition to previous studies, which have found that this allele is associated with improved treatment response.[@B17][@B18][@B36] Contini et al.[@B53] reported no difference in methylphenidate treatment response between *ADRA2A* G and C allele carriers. Differences in the ethnicity and heterogeneity of the study groups evaluated in the various reports may account for these apparent discrepancies.

The present study may be limited as a result of the exclusive inclusion of patients from a tertiary medical center. Consequently, these results may be difficult to generalize for the wider population. The naturalistic study design and the loss of 13 patients during the assessment procedure also limited the data collection. However, the patients were assessed using multiple clinical scales, neuropsychological tests, and co-morbidities in an effort to generate homogenous study groups. The control group included a significant number of subjects selected from a gender-matched population sample.

As a result, our study data indicates that *ADRA2A* (rs1800544) SNP, low socioeconomic status, and the presence of psychiatric co-morbidities are associated with increased risk of poor methylphenidate response in ADHD. Drug free treatment plans including psychosocial interventions may be more suitable for patients with these risk factors. Our data regarding *ADRA2A* polymorphism is among the few ADHD polymorphism studies conducted in Turkish population. The incorporation of phenotyping in ADHD treatment may be premature, and as a result, more studies regarding genetic polymorphisms associated with ADHD are necessary to advance this field.
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